Elevation of KL-6 serum levels in clinical trials of tumor necrosis factor inhibitors in patients with rheumatoid arthritis: A report from the Japan College of Rheumatology Ad Hoc Committee for Safety of Biological DMARDs

Modern Rheumatology

Volumn 23, Issue 2, 2013, Pages 284-296

  Harigai, Masayoshi ^a,b   Takamura, Akito ^a,b   Atsumi, Tatsuya ^a,c   Dohi, Makoto ^a,d   Hirata, Shintaro ^a,e   Kameda, Hideto ^a,f   Nagasawa, Hayato ^a,g   Seto, Yohei ^a,h   Koike, Takao ⁱ   Miyasaka, Nobuyuki ^b  

^a Japan College of Rheumatology   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^f Medical Research Division   (Japan)

^g SAITAMA MEDICAL UNIVERSITY   (Japan)

^h TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

ⁱ NTT CORPORATION   (Japan)

Author keywords

Biological disease modifying antirheumatic drug; Interstitial pneumonia; KL 6; Pneumocystis jirovecii pneumonia; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; CERTOLIZUMAB PEGOL; IMMUNOGLOBULIN F(AB) FRAGMENT; MACROGOL DERIVATIVE; METHOTREXATE; MONOCLONAL ANTIBODY; MUC1 PROTEIN, HUMAN; MUCIN 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG COMBINATION; FEMALE; HUMAN; MALE; MIDDLE AGED; RHEUMATOID ARTHRITIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; METHOTREXATE; MIDDLE AGED; MUCIN-1; POLYETHYLENE GLYCOLS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84883143578     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-012-0657-2     Document Type: Article

References (22)

1. Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67: 189-94.
2. Koike T, Harigai M, Inokuma S, Inoue K, Ishiguro N, Ryu J, et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol. 2009;36: 898-906.
3. Komano Y, Harigai M, Koike R, Sugiyama H, Ogawa J, Saito K, et al. Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum. 2009;61: 305-12.
4. Harigai M, Koike R, Miyasaka N. Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med. 2007;357: 1874-6.
5. Stahel RA, Gilks WR, Lehmann HP, Schenker T. Third International Workshop on Lung Tumor and Differentiation Antigens: overview of the results of the central data analysis. Int J Cancer Suppl. 1994;8: 6-26.
6. Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest. 1989;96: 68-73.
7. Ishizaka A, Matsuda T, Albertine KH, Koh H, Tasaka S, Hasegawa N, et al. Elevation of KL-6, a lung epithelial cell marker, in plasma and epithelial lining fluid in acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol. 2004;286: L1088-94.
8. Kohno N, Awaya Y, Oyama T, Yamakido M, Akiyama M, Inoue Y, et al. KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Am Rev Respir Dis. 1993;148: 637-42.
9. Oyama T, Kohno N, Yokoyama A, Hirasawa Y, Hiwada K, Oyama H, et al. Detection of interstitial pneumonitis in patients with rheumatoid arthritis by measuring circulating levels of KL- 6, a human MUC1 mucin. Lung. 1997;175: 379-85.
10. Hamada H, Kohno N, Yokoyama A, Hirasawa Y, Hiwada K, Sakatani M, et al. KL-6 as a serologic indicator of Pneumocystis carinii pneumonia in immunocompromised hosts. Intern Med. 1998;37: 307-10.
11. Kohno N. Serum marker KL-6/MUC1 for the diagnosis and management of interstitial pneumonitis. J Med Invest. 1999;46: 151-8.
12. Sato H, Callister ME, Mumby S, Quinlan GJ, Welsh KI, duBois RM, et al. KL-6 levels are elevated in plasma from patients with acute respiratory distress syndrome. Eur Respir J. 2004;23: 142-5.
13. Kondo T, Hattori N, Ishikawa N, Murai H, Haruta Y, Hirohashi N, et al. KL-6 concentration in pulmonary epithelial lining fluid is a useful prognostic indicator in patients with acute respiratory distress syndrome. Respir Res. 2011;12:32.
14. Nakajima H, Harigai M, Hara M, Hakoda M, Tokuda H, Sakai F, et al. KL-6 as a novel serum marker for interstitial pneumonia associated with collagen diseases. J Rheumatol. 2000;27: 1164-70.
15. Takeuchi T, Miyasaka N, Inoue K, Abe T, Koike T. Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. Mod Rheumatol. 2009;19: 478-87.
16. Koiwa M, Goto S, Takenouchi K, Takahasi K, Kamada T, Nakamura H. Elevation of serum KL-6 levels in 3 patients with rheumatoid arthritis treated with adalimumab. Mod Rheumatol. 2012;22: 147-51.
17. Tanaka Y, Harigai M, Takeuchi T, Yamanaka H, Ishiguro N, Yamamoto K, et al. Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study. Ann Rheum Dis. 2012;71: 817-824.
18. Tanaka Y, Harigai M, Takeuchi T, Yamanaka H, Ishiguro N, Yamamoto K, et al. Golimumab, a human anti-TNFalpha monoclonal antibody administered subcutaneously every four weeks in patients active rheumatoid arthritis despite methotrexate therapy: 24-week results of clinical and radiographic assessments. Arthritis Rheum. 2010;62:S757.
19. Honda Y, Kuroki Y, Matsuura E, Nagae H, Takahashi H, Akino T, et al. Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med. 1995;152: 1860-6.
20. Takeuchi T, Kameda H. The Japanese experience with biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 2010;6: 644-52.
21. Tasaka S, Hasegawa N, Kobayashi S, Yamada W, Nishimura T, Takeuchi T, et al. Serum indicators for the diagnosis of pneumocystis pneumonia. Chest. 2007;131: 1173-80.
22. Takamura A, Hirata S, Nagasawa H, Kameda H, Seto Y, Atsumi T, et al. A retrospective study of serum KL-6 levels during treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients-a report from the ad-hoc committee for safety of biological DMARDs of the Japan College of Rheumatology. Mod Rheumatol. 2012. doi:10.1007/s10165-012-0658-1